Author: "Brunner, Fabian J" / Publication Type: Electronic Resources - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Brunner, Fabian J"' showing total 23 results

Start Over Author "Brunner, Fabian J" Publication Type Electronic Resources

23 results on '"Brunner, Fabian J"'

1. C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease:the BiomarCaRE project

Author: Arnold, Natalie, Blaum, Christopher, Goßling, Alina, Brunner, Fabian J., Bay, Benjamin, Ferrario, Marco M., Brambilla, Paolo, Cesana, Giancarlo, Leoni, Valerio, Palmieri, Luigi, Donfrancesco, Chiara, Padró, Teresa, Andersson, Jonas, Jousilahti, Pekka, Ojeda, Francisco, Zeller, Tanja, Linneberg, Allan, Söderberg, Stefan, Iacoviello, Licia, Gianfagna, Francesco, Sans, Susana, Veronesi, Giovanni, Thorand, Barbara, Peters, Annette, Tunstall-Pedoe, Hugh, Kee, Frank, Salomaa, Veikko, Schnabel, Renate B., Kuulasmaa, Kari, Blankenberg, Stefan, Koenig, Wolfgang, Waldeyer, Christoph, Arnold, Natalie, Blaum, Christopher, Goßling, Alina, Brunner, Fabian J., Bay, Benjamin, Ferrario, Marco M., Brambilla, Paolo, Cesana, Giancarlo, Leoni, Valerio, Palmieri, Luigi, Donfrancesco, Chiara, Padró, Teresa, Andersson, Jonas, Jousilahti, Pekka, Ojeda, Francisco, Zeller, Tanja, Linneberg, Allan, Söderberg, Stefan, Iacoviello, Licia, Gianfagna, Francesco, Sans, Susana, Veronesi, Giovanni, Thorand, Barbara, Peters, Annette, Tunstall-Pedoe, Hugh, Kee, Frank, Salomaa, Veikko, Schnabel, Renate B., Kuulasmaa, Kari, Blankenberg, Stefan, Koenig, Wolfgang, and Waldeyer, Christoph
Abstract: Background and Aims Recent investigations have suggested an interdependence of lipoprotein(a) [Lp(a)]-related risk for cardiovascular disease with background inflammatory burden. The aim the present analysis was to investigate whether high-sensitive C-reactive protein (hsCRP) modulates the association between Lp(a) and coronary heart disease (CHD) in the general population. Methods Data from 71 678 participants from 8 European prospective population-based cohort studies were used (65 661 without/6017 with established CHD at baseline; median follow-up 9.8/13.8 years, respectively). Fine and Gray competing risk-adjusted models were calculated according to accompanying hsCRP concentration (<2 and ≥2 mg/L). Results Among CHD-free individuals, increased Lp(a) levels were associated with incident CHD irrespective of hsCRP concentration: fully adjusted sub-distribution hazard ratios [sHRs (95% confidence interval)] for the highest vs. lowest fifth of Lp(a) distribution were 1.45 (1.23–1.72) and 1.48 (1.23–1.78) for a hsCRP group of <2 and ≥2 mg/L, respectively, with no interaction found between these two biomarkers on CHD risk (Pinteraction = 0.82). In those with established CHD, similar associations were seen only among individuals with hsCRP ≥ 2 mg/L [1.34 (1.03–1.76)], whereas among participants with a hsCRP concentration <2 mg/L, there was no clear association between Lp(a) and future CHD events [1.29 (0.98–1.71)] (highest vs. lowest fifth, fully adjusted models; Pinteraction = 0.024). Conclusions While among CHD-free individuals Lp(a) was significantly associated with incident CHD regardless of hsCRP, in participants with CHD at baseline, Lp(a) was related to recurrent CHD events only in those with residual inflammatory risk. These findings might guide adequate selection of high-risk patients for forthcoming Lp(a)-targeting compounds., Background and Aims Recent investigations have suggested an interdependence of lipoprotein(a) [Lp(a)]-related risk for cardiovascular disease with background inflammatory burden. The aim the present analysis was to investigate whether high-sensitive C-reactive protein (hsCRP) modulates the association between Lp(a) and coronary heart disease (CHD) in the general population. Methods Data from 71 678 participants from 8 European prospective population-based cohort studies were used (65 661 without/6017 with established CHD at baseline; median follow-up 9.8/13.8 years, respectively). Fine and Gray competing risk-adjusted models were calculated according to accompanying hsCRP concentration (<2 and ≥2 mg/L). Results Among CHD-free individuals, increased Lp(a) levels were associated with incident CHD irrespective of hsCRP concentration: fully adjusted sub-distribution hazard ratios [sHRs (95% confidence interval)] for the highest vs. lowest fifth of Lp(a) distribution were 1.45 (1.23-1.72) and 1.48 (1.23-1.78) for a hsCRP group of <2 and ≥2 mg/L, respectively, with no interaction found between these two biomarkers on CHD risk (Pinteraction = 0.82). In those with established CHD, similar associations were seen only among individuals with hsCRP ≥ 2 mg/L [1.34 (1.03-1.76)], whereas among participants with a hsCRP concentration <2 mg/L, there was no clear association between Lp(a) and future CHD events [1.29 (0.98-1.71)] (highest vs. lowest fifth, fully adjusted models; Pinteraction = 0.024). Conclusions While among CHD-free individuals Lp(a) was significantly associated with incident CHD regardless of hsCRP, in participants with CHD at baseline, Lp(a) was related to recurrent CHD events only in those with residual inflammatory risk. These findings might guide adequate selection of high-risk patients for forthcoming Lp(a)-targeting compounds.
Published: 2024

2. Deep learning for calcium segmentation in intravascular ultrasound images

Author: Holstein, Lennart, Riedl, Katharina Alina, Wissel, Tobias, Brunner, Fabian J., Schaefers, Klaus, Graß, Michael, Blankenberg, Stefan, Seiffert, Moritz, Schlaefer, Alexander, Holstein, Lennart, Riedl, Katharina Alina, Wissel, Tobias, Brunner, Fabian J., Schaefers, Klaus, Graß, Michael, Blankenberg, Stefan, Seiffert, Moritz, and Schlaefer, Alexander
Abstract: Knowing the shape of vascular calcifications is crucial for appropriate planning and conductance of percutaneous coronary interventions. The clinical workflow can therefore benefit from automatic segmentation of calcified plaques in intravascular ultrasound (IVUS) images. To solve segmentation problems with convolutional neural networks (CNNs), large datasets are usually required. However, datasets are often rather small in the medical domain. Hence, developing and investigating methods for increasing CNN performance on small datasets can help on the way towards clinically relevant results. We compared two state-of-the-art CNN architectures for segmentation, U-Net and DeepLabV3, and investigated how incorporating auxiliary image data with vessel wall and lumen annotations improves the calcium segmentation performance by using these either for pretraining or multi-task training. DeepLabV3 outperforms U-Net with up to 6.3 % by means of the Dice coefficient and 36.5 % by means of the average Hausdorff distance. Using auxiliary data improves the segmentation performance in both cases, whereas the multi-task approach outperforms the pre-training approach. The improvements of the multi-task approach in contrast to not using auxiliary data at all is 5.7 % for the Dice coefficient and 42.9 % for the average Hausdorff distance. Automatic segmentation of calcified plaques in IVUS images is a demanding task due to their relatively small size compared to the image dimensions and due to visual ambiguities with other image structures. We showed that this problem can generally be tackled by CNNs. Furthermore, we were able to improve the performance by a multi-task learning approach with auxiliary segmentation data.
Published: 2021

3. Deep learning for guidewire detection in intravascular ultrasound images

Author: Bargsten, Lennart, Klisch, Daniel, Riedl, Katharina Alina, Wissel, Tobias, Brunner, Fabian J., Schaefers, Klaus, Graß, Michael, Blankenberg, Stefan, Seiffert, Moritz, Schlaefer, Alexander, Bargsten, Lennart, Klisch, Daniel, Riedl, Katharina Alina, Wissel, Tobias, Brunner, Fabian J., Schaefers, Klaus, Graß, Michael, Blankenberg, Stefan, Seiffert, Moritz, and Schlaefer, Alexander
Abstract: Algorithms for automated analysis of intravascular ultrasound (IVUS) images can be disturbed by guidewires, which are often encountered when treating bifurcations in percutaneous coronary interventions. Detecting guidewires in advance can therefore help avoiding potential errors. This task is not trivial, since guidewires appear rather small compared to other relevant objects in IVUS images. We employed CNNs with additional multi-task learning as well as different guidewire-specific regularizations to enable and improve guidewire detection. In this context, we developed a network block which generates heatmaps that highlight guidewires without the need of localization annotations. The guidewire detection results reach values of 0.931 in terms of the F1-score and 0.996 in terms of area under curve (AUC). Comparing thresholded guidewire heatmaps with ground truth segmentation masks leads to a Dice score of 23.1 % and an average Hausdorff distance of 1.45 mm. Guidewire detection has proven to be a task that CNNs can handle quite well. Employing multi-task learning and guidewire-specific regularizations further improve detection results and enable generation of heatmaps that indicate the position of guidewires without actual labels.
Published: 2021

4. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48.7%] women; median age 51.0 years [IQR 40.7-59.7]). 199 415 individuals were included in the derivation cohort (91 786 [48.4%] women) and 199 431 (92 269 [49.1%] women) in the validation cohort. During a maximum follow-up of 43.6 years (median 13.5 years, IQR 7.0-20.1), 54 542 cardiovascular endpoints occurred. Incidence curv
Published: 2019
Full Text: View/download PDF

5. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidence c
Published: 2019
Full Text: View/download PDF

6. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidence c
Published: 2019
Full Text: View/download PDF

7. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48.7%] women; median age 51.0 years [IQR 40.7-59.7]). 199 415 individuals were included in the derivation cohort (91 786 [48.4%] women) and 199 431 (92 269 [49.1%] women) in the validation cohort. During a maximum follow-up of 43.6 years (median 13.5 years, IQR 7.0-20.1), 54 542 cardiovascular endpoints occurred. Incidence curv
Published: 2019
Full Text: View/download PDF

8. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidence c
Published: 2019
Full Text: View/download PDF

9. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48.7%] women; median age 51.0 years [IQR 40.7-59.7]). 199 415 individuals were included in the derivation cohort (91 786 [48.4%] women) and 199 431 (92 269 [49.1%] women) in the validation cohort. During a maximum follow-up of 43.6 years (median 13.5 years, IQR 7.0-20.1), 54 542 cardiovascular endpoints occurred. Incidence curv
Published: 2019
Full Text: View/download PDF

10. Application of non-HDL cholesterol for population-based cardiovascular risk stratification:results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P.F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J.L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, Koenig, Wolfgang, Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P.F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J.L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, and Koenig, Wolfgang
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidenc
Published: 2019

11. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, F, Waldeyer, C, Ojeda, F, Salomaa, V, Kee, F, Sans, S, Thorand, B, Giampaoli, S, Brambilla, P, Tunstall-Pedoe, H, Moitry, M, Iacoviello, L, Veronesi, G, Grassi, G, Mathiesen, E, Söderberg, S, Linneberg, A, Brenner, H, Amouyel, P, Ferrières, J, Tamosiunas, A, Nikitin, Y, Drygas, W, Melander, O, Jöckel, K, Leistner, D, Shaw, J, Panagiotakos, D, Simons, L, Kavousi, M, Vasan, R, Dullaart, R, Wannamethee, S, Risérus, U, Shea, S, de Lemos, J, Omland, T, Kuulasmaa, K, Landmesser, U, Blankenberg, S, Zeller, T, Kontto, J, Männistö, S, Metspalu, A, Lackner, K, Wild, P, Peters, A, Meisinger, C, Donfrancesco, C, Signorini, S, Alver, M, Woodward, M, Gianfagna, F, Costanzo, S, Wilsgaard, T, Eliasson, M, Jørgensen, T, Völzke, H, Dörr, M, Nauck, M, Schöttker, B, Lorenz, T, Makarova, N, Twerenbold, R, Dallongeville, J, Dobson, A, Malyutina, S, Pajak, A, Engström, G, Bobak, M, Schmidt, B, Jääskeläinen, T, Niiranen, T, Jousilahti, P, Giles, G, Hodge, A, Klotsche, J, Magliano, D, Lyngbakken, M, Hveem, K, Pitsavos, C, Benjamin, E, Bakker, S, Whincup, P, Ikram, M, Ingelsson, M, Koenig, W, Brunner, Fabian J, Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B, Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P, Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M, Shaw, Jonathan E, Panagiotakos, Demosthenes B, Simons, Leon A, Kavousi, Maryam, Vasan, Ramachandran S, Dullaart, Robin P F, Wannamethee, S Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A, Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J. L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, Koenig, Wolfgang, Brunner, F, Waldeyer, C, Ojeda, F, Salomaa, V, Kee, F, Sans, S, Thorand, B, Giampaoli, S, Brambilla, P, Tunstall-Pedoe, H, Moitry, M, Iacoviello, L, Veronesi, G, Grassi, G, Mathiesen, E, Söderberg, S, Linneberg, A, Brenner, H, Amouyel, P, Ferrières, J, Tamosiunas, A, Nikitin, Y, Drygas, W, Melander, O, Jöckel, K, Leistner, D, Shaw, J, Panagiotakos, D, Simons, L, Kavousi, M, Vasan, R, Dullaart, R, Wannamethee, S, Risérus, U, Shea, S, de Lemos, J, Omland, T, Kuulasmaa, K, Landmesser, U, Blankenberg, S, Zeller, T, Kontto, J, Männistö, S, Metspalu, A, Lackner, K, Wild, P, Peters, A, Meisinger, C, Donfrancesco, C, Signorini, S, Alver, M, Woodward, M, Gianfagna, F, Costanzo, S, Wilsgaard, T, Eliasson, M, Jørgensen, T, Völzke, H, Dörr, M, Nauck, M, Schöttker, B, Lorenz, T, Makarova, N, Twerenbold, R, Dallongeville, J, Dobson, A, Malyutina, S, Pajak, A, Engström, G, Bobak, M, Schmidt, B, Jääskeläinen, T, Niiranen, T, Jousilahti, P, Giles, G, Hodge, A, Klotsche, J, Magliano, D, Lyngbakken, M, Hveem, K, Pitsavos, C, Benjamin, E, Bakker, S, Whincup, P, Ikram, M, Ingelsson, M, Koenig, W, Brunner, Fabian J, Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B, Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P, Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M, Shaw, Jonathan E, Panagiotakos, Demosthenes B, Simons, Leon A, Kavousi, Maryam, Vasan, Ramachandran S, Dullaart, Robin P F, Wannamethee, S Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A, Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J. L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, and Koenig, Wolfgang
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidence c
Published: 2019

12. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidence c
Published: 2019
Full Text: View/download PDF

13. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48.7%] women; median age 51.0 years [IQR 40.7-59.7]). 199 415 individuals were included in the derivation cohort (91 786 [48.4%] women) and 199 431 (92 269 [49.1%] women) in the validation cohort. During a maximum follow-up of 43.6 years (median 13.5 years, IQR 7.0-20.1), 54 542 cardiovascular endpoints occurred. Incidence curv
Published: 2019
Full Text: View/download PDF

14. Application of non-HDL cholesterol for population-based cardiovascular risk stratification:results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P.F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J.L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, Koenig, Wolfgang, Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P.F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J.L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, and Koenig, Wolfgang
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidenc
Published: 2019

15. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, F, Waldeyer, C, Ojeda, F, Salomaa, V, Kee, F, Sans, S, Thorand, B, Giampaoli, S, Brambilla, P, Tunstall-Pedoe, H, Moitry, M, Iacoviello, L, Veronesi, G, Grassi, G, Mathiesen, E, Söderberg, S, Linneberg, A, Brenner, H, Amouyel, P, Ferrières, J, Tamosiunas, A, Nikitin, Y, Drygas, W, Melander, O, Jöckel, K, Leistner, D, Shaw, J, Panagiotakos, D, Simons, L, Kavousi, M, Vasan, R, Dullaart, R, Wannamethee, S, Risérus, U, Shea, S, de Lemos, J, Omland, T, Kuulasmaa, K, Landmesser, U, Blankenberg, S, Zeller, T, Kontto, J, Männistö, S, Metspalu, A, Lackner, K, Wild, P, Peters, A, Meisinger, C, Donfrancesco, C, Signorini, S, Alver, M, Woodward, M, Gianfagna, F, Costanzo, S, Wilsgaard, T, Eliasson, M, Jørgensen, T, Völzke, H, Dörr, M, Nauck, M, Schöttker, B, Lorenz, T, Makarova, N, Twerenbold, R, Dallongeville, J, Dobson, A, Malyutina, S, Pajak, A, Engström, G, Bobak, M, Schmidt, B, Jääskeläinen, T, Niiranen, T, Jousilahti, P, Giles, G, Hodge, A, Klotsche, J, Magliano, D, Lyngbakken, M, Hveem, K, Pitsavos, C, Benjamin, E, Bakker, S, Whincup, P, Ikram, M, Ingelsson, M, Koenig, W, Brunner, Fabian J, Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B, Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P, Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M, Shaw, Jonathan E, Panagiotakos, Demosthenes B, Simons, Leon A, Kavousi, Maryam, Vasan, Ramachandran S, Dullaart, Robin P F, Wannamethee, S Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A, Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J. L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, Koenig, Wolfgang, Brunner, F, Waldeyer, C, Ojeda, F, Salomaa, V, Kee, F, Sans, S, Thorand, B, Giampaoli, S, Brambilla, P, Tunstall-Pedoe, H, Moitry, M, Iacoviello, L, Veronesi, G, Grassi, G, Mathiesen, E, Söderberg, S, Linneberg, A, Brenner, H, Amouyel, P, Ferrières, J, Tamosiunas, A, Nikitin, Y, Drygas, W, Melander, O, Jöckel, K, Leistner, D, Shaw, J, Panagiotakos, D, Simons, L, Kavousi, M, Vasan, R, Dullaart, R, Wannamethee, S, Risérus, U, Shea, S, de Lemos, J, Omland, T, Kuulasmaa, K, Landmesser, U, Blankenberg, S, Zeller, T, Kontto, J, Männistö, S, Metspalu, A, Lackner, K, Wild, P, Peters, A, Meisinger, C, Donfrancesco, C, Signorini, S, Alver, M, Woodward, M, Gianfagna, F, Costanzo, S, Wilsgaard, T, Eliasson, M, Jørgensen, T, Völzke, H, Dörr, M, Nauck, M, Schöttker, B, Lorenz, T, Makarova, N, Twerenbold, R, Dallongeville, J, Dobson, A, Malyutina, S, Pajak, A, Engström, G, Bobak, M, Schmidt, B, Jääskeläinen, T, Niiranen, T, Jousilahti, P, Giles, G, Hodge, A, Klotsche, J, Magliano, D, Lyngbakken, M, Hveem, K, Pitsavos, C, Benjamin, E, Bakker, S, Whincup, P, Ikram, M, Ingelsson, M, Koenig, W, Brunner, Fabian J, Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B, Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P, Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M, Shaw, Jonathan E, Panagiotakos, Demosthenes B, Simons, Leon A, Kavousi, Maryam, Vasan, Ramachandran S, Dullaart, Robin P F, Wannamethee, S Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A, Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J. L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, and Koenig, Wolfgang
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidence c
Published: 2019

16. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidence c
Published: 2019
Full Text: View/download PDF

17. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Soderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Joeckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48.7%] women; median age 51.0 years [IQR 40.7-59.7]). 199 415 individuals were included in the derivation cohort (91 786 [48.4%] women) and 199 431 (92 269 [49.1%] women) in the validation cohort. During a maximum follow-up of 43.6 years (median 13.5 years, IQR 7.0-20.1), 54 542 cardiovascular endpoints occurred. Incidence curv
Published: 2019
Full Text: View/download PDF

18. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., Ikram, M. K., Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrieres, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl-Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P. F., Wannamethee, S. Goya, Riserus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjorn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, T., Lackner, K., Wild, P., Peters, A., Meisinger, C., Voelzke, H., Doerr, M., Nauck, M., Schoettker, B., Lorenz, T., Makarova, N., Schmidt, B., Klotsche, J., Koenig, W., Kontto, J., Mannisto, S., Jaaskelainen, T., Niiranen, T., Jousilahti, P., Metspalu, A., Alver, M., Donfrancesco, C., Signorini, S. G., Gianfagna, F., Costanzo, S., Woodward, M., Dobson, A., Giles, G., Hodge, A., Magliano, D. J., Wilsgaard, T., Lyngbakken, M. N., Hveem, K., Eliasson, M., Engstrom, G., Ingelsson, M., Jorgensen, T., Twerenbold, R., Dallongeville, J., Malyutina, S., Pajak, A., Bobak, M., Whincup, P., Pitsavos, C., Benjamin, E. J., Bakker, S. J. L., and Ikram, M. K.
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidence c
Published: 2019
Full Text: View/download PDF

19. Application of non-HDL cholesterol for population-based cardiovascular risk stratification:results from the Multinational Cardiovascular Risk Consortium

Author: Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P.F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J.L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, Koenig, Wolfgang, Brunner, Fabian J., Waldeyer, Christoph, Ojeda, Francisco, Salomaa, Veikko, Kee, Frank, Sans, Susana, Thorand, Barbara, Giampaoli, Simona, Brambilla, Paolo, Tunstall-Pedoe, Hugh, Moitry, Marie, Iacoviello, Licia, Veronesi, Giovanni, Grassi, Guido, Mathiesen, Ellisiv B., Söderberg, Stefan, Linneberg, Allan, Brenner, Hermann, Amouyel, Philippe, Ferrières, Jean, Tamosiunas, Abdonas, Nikitin, Yuriy P., Drygas, Wojciech, Melander, Olle, Jöckel, Karl Heinz, Leistner, David M., Shaw, Jonathan E., Panagiotakos, Demosthenes B., Simons, Leon A., Kavousi, Maryam, Vasan, Ramachandran S., Dullaart, Robin P.F., Wannamethee, S. Goya, Risérus, Ulf, Shea, Steven, de Lemos, James A., Omland, Torbjørn, Kuulasmaa, Kari, Landmesser, Ulf, Blankenberg, Stefan, Zeller, Tanja, Kontto, Jukka, Männistö, Satu, Metspalu, Andres, Lackner, Karl, Wild, Philipp, Peters, Annette, Meisinger, Christa, Donfrancesco, Chiara, Signorini, Stefano G., Alver, Maris, Woodward, Mark, Gianfagna, Francesco, Costanzo, Simona, Wilsgaard, Tom, Eliasson, Mats, Jørgensen, Torben, Völzke, Henry, Dörr, Marcus, Nauck, Matthias, Schöttker, Ben, Lorenz, Thiess, Makarova, Nataliya, Twerenbold, Raphael, Dallongeville, Jean, Dobson, Annette, Malyutina, Sofia, Pajak, Andrzej, Engström, Gunnar, Bobak, Martin, Schmidt, Börge, Jääskeläinen, Tuija, Niiranen, Teemu, Jousilahti, Pekka, Giles, Graham, Hodge, Allison, Klotsche, Jens, Magliano, Dianna J., Lyngbakken, Magnus N., Hveem, Kristian, Pitsavos, Christos, Benjamin, Emelia J., Bakker, Stephan J.L., Whincup, Peter, Ikram, M. Kamran, Ingelsson, Martin, and Koenig, Wolfgang
Abstract: Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidenc
Published: 2019

20. Gender-specific diagnostic performance of a new high-sensitivity cardiac troponin I assay for detection of acute myocardial infarction

Author: Schofer, Niklas, Brunner, Fabian J., Schlueter, Michael, Ojeda, Francisco, Zeller, Tanja, Baldus, Stephan, Bickel, Christoph, Lackner, Karl J., Muenzel, Thomas, Tzikas, Stergios, Genth-Zotz, Sabine, Warnholtz, Ascan, Post, Felix, Keller, Till, Goldmann, Britta U., Blankenberg, Stefan, Schofer, Niklas, Brunner, Fabian J., Schlueter, Michael, Ojeda, Francisco, Zeller, Tanja, Baldus, Stephan, Bickel, Christoph, Lackner, Karl J., Muenzel, Thomas, Tzikas, Stergios, Genth-Zotz, Sabine, Warnholtz, Ascan, Post, Felix, Keller, Till, Goldmann, Britta U., and Blankenberg, Stefan
Abstract: Background: The determination of cardiac troponin is essential for diagnosing myocardial infarction. A troponin I assay has recently been developed that provides the highest analytical sensitivity to date. Methods: The analysis included 1560 patients with chest pain, of whom 1098 were diagnosed with non-coronary chest pain, 189 with unstable angina pectoris and 273 with non-ST-segment elevation myocardial infarction. The troponin I concentration was determined on admission (0 hours) and 3 hours later. The diagnostic algorithm incorporated troponin I elevation above the gender-specific 99th percentile as well as predefined relative or absolute 3-hour changes in the troponin I concentration (delta). Results: The diagnostic criterion of troponin I above the 99th percentile resulted in a negative predictive value of 98.0% and 98.2% in men and women, respectively. For rule-in of non-ST-segment elevation myocardial infarction, the use of absolute deltas yielded higher positive predictive values and sensitivities compared to relative deltas. With detection rates of about 85% and 82% in men and women, respectively, non-ST-segment elevation myocardial infarction was diagnosed with a positive predictive value close to 84% in men and 80% in women. Conclusions: The investigational troponin I assay provides an excellent non-ST-segment elevation myocardial infarction rule out. With gender-specific differences, the application of absolute changes in troponin concentration was superior to relative changes to rule in patients with non-ST-segment elevation myocardial infarction.
Published: 2017

21. Gender-specific diagnostic performance of a new high-sensitivity cardiac troponin I assay for detection of acute myocardial infarction

Author: Schofer, Niklas, Brunner, Fabian J., Schlueter, Michael, Ojeda, Francisco, Zeller, Tanja, Baldus, Stephan, Bickel, Christoph, Lackner, Karl J., Muenzel, Thomas, Tzikas, Stergios, Genth-Zotz, Sabine, Warnholtz, Ascan, Post, Felix, Keller, Till, Goldmann, Britta U., Blankenberg, Stefan, Schofer, Niklas, Brunner, Fabian J., Schlueter, Michael, Ojeda, Francisco, Zeller, Tanja, Baldus, Stephan, Bickel, Christoph, Lackner, Karl J., Muenzel, Thomas, Tzikas, Stergios, Genth-Zotz, Sabine, Warnholtz, Ascan, Post, Felix, Keller, Till, Goldmann, Britta U., and Blankenberg, Stefan
Abstract: Background: The determination of cardiac troponin is essential for diagnosing myocardial infarction. A troponin I assay has recently been developed that provides the highest analytical sensitivity to date. Methods: The analysis included 1560 patients with chest pain, of whom 1098 were diagnosed with non-coronary chest pain, 189 with unstable angina pectoris and 273 with non-ST-segment elevation myocardial infarction. The troponin I concentration was determined on admission (0 hours) and 3 hours later. The diagnostic algorithm incorporated troponin I elevation above the gender-specific 99th percentile as well as predefined relative or absolute 3-hour changes in the troponin I concentration (delta). Results: The diagnostic criterion of troponin I above the 99th percentile resulted in a negative predictive value of 98.0% and 98.2% in men and women, respectively. For rule-in of non-ST-segment elevation myocardial infarction, the use of absolute deltas yielded higher positive predictive values and sensitivities compared to relative deltas. With detection rates of about 85% and 82% in men and women, respectively, non-ST-segment elevation myocardial infarction was diagnosed with a positive predictive value close to 84% in men and 80% in women. Conclusions: The investigational troponin I assay provides an excellent non-ST-segment elevation myocardial infarction rule out. With gender-specific differences, the application of absolute changes in troponin concentration was superior to relative changes to rule in patients with non-ST-segment elevation myocardial infarction.
Published: 2017

22. Lipoprotein(a) and the risk of cardiovascular disease in the European population:Results from the BiomarCaRE consortium

Author: Waldeyer, Christoph, Makarova, Nataliya, Zeller, Tanja, Schnabel, Renate B., Brunner, Fabian J., Jørgensen, Torben, Linneberg, Allan, Niiranen, Teemu, Salomaa, Veikko, Jousilahti, Pekka, Yarnell, John, Ferrario, Marco M., Veronesi, Giovanni, Brambilla, Paolo, Signorini, Stefano G., Iacoviello, Licia, Costanzo, Simona, Giampaoli, Simona, Palmieri, Luigi, Meisinger, Christa, Thorand, Barbara, Kee, Frank, Koenig, Wolfgang, Ojeda, Francisco, Kontto, Jukka, Landmesser, Ulf, Kuulasmaa, Kari, Blankenberg, Stefan, Waldeyer, Christoph, Makarova, Nataliya, Zeller, Tanja, Schnabel, Renate B., Brunner, Fabian J., Jørgensen, Torben, Linneberg, Allan, Niiranen, Teemu, Salomaa, Veikko, Jousilahti, Pekka, Yarnell, John, Ferrario, Marco M., Veronesi, Giovanni, Brambilla, Paolo, Signorini, Stefano G., Iacoviello, Licia, Costanzo, Simona, Giampaoli, Simona, Palmieri, Luigi, Meisinger, Christa, Thorand, Barbara, Kee, Frank, Koenig, Wolfgang, Ojeda, Francisco, Kontto, Jukka, Landmesser, Ulf, Kuulasmaa, Kari, and Blankenberg, Stefan
Abstract: Aims: As promising compounds to lower Lipoprotein(a) (Lp(a)) are emerging, the need for a precise characterization and comparability of the Lp(a)-associated cardiovascular risk is increasing. Therefore, we aimed to evaluate the distribution of Lp(a) concentrations across the European population, to characterize the association with cardiovascular outcomes and to provide high comparability of the Lp(a)-associated cardiovascular risk by use of centrally determined Lp(a) concentrations. Methods and results: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE)-project, we analysed data of 56 804 participants from 7 prospective population-based cohorts across Europe with a maximum follow-up of 24 years. All Lp(a) measurements were performed in the central BiomarCaRE laboratory (Biokit Quantia Lp(a)- Test; Abbott Diagnostics). The three endpoints considered were incident major coronary events (MCE), incident cardiovascular disease (CVD) events, and total mortality. We found lower Lp(a) levels in Northern European cohorts (median 4.9mg/dL) compared to central (median 7.9mg/ dL) and Southern European cohorts (10.9 mg/dL) (Jonckheere-Terpstra test P< 0.001). Kaplan-Meier curves showed the highest event rate of MCE and CVD events for Lp(a) levels≥90th percentile (log-rank test: P< 0.001 for MCE and CVD). Cox regression models adjusted for age, sex, and cardiovascular risk factors revealed a significant association of Lp(a) levels with MCE and CVD with a hazard ratio (HR) of 1.30 for MCE [95% confidence interval (CI) 1.15- 1.46] and of 1.25 for CVD (95% CI 1.12-1.39) for Lp(a) levels in the 67-89th percentile and a HR of 1.49 for MCE (95% CI 1.29-1.73) and of 1.44 for CVD (95% CI 1.25-1.65) for Lp(a) levels≥ 90th percentile vs. Lp(a) levels in the lowest third (P< 0.001 for all). There was no significant association between Lp(a) levels and total mortality Subgroup analysis for a continuous version of cube root transformed Lp(a)
Published: 2017

23. Lipoprotein(a) and the risk of cardiovascular disease in the European population:Results from the BiomarCaRE consortium

Author: Waldeyer, Christoph, Makarova, Nataliya, Zeller, Tanja, Schnabel, Renate B., Brunner, Fabian J., Jørgensen, Torben, Linneberg, Allan, Niiranen, Teemu, Salomaa, Veikko, Jousilahti, Pekka, Yarnell, John, Ferrario, Marco M., Veronesi, Giovanni, Brambilla, Paolo, Signorini, Stefano G., Iacoviello, Licia, Costanzo, Simona, Giampaoli, Simona, Palmieri, Luigi, Meisinger, Christa, Thorand, Barbara, Kee, Frank, Koenig, Wolfgang, Ojeda, Francisco, Kontto, Jukka, Landmesser, Ulf, Kuulasmaa, Kari, Blankenberg, Stefan, Waldeyer, Christoph, Makarova, Nataliya, Zeller, Tanja, Schnabel, Renate B., Brunner, Fabian J., Jørgensen, Torben, Linneberg, Allan, Niiranen, Teemu, Salomaa, Veikko, Jousilahti, Pekka, Yarnell, John, Ferrario, Marco M., Veronesi, Giovanni, Brambilla, Paolo, Signorini, Stefano G., Iacoviello, Licia, Costanzo, Simona, Giampaoli, Simona, Palmieri, Luigi, Meisinger, Christa, Thorand, Barbara, Kee, Frank, Koenig, Wolfgang, Ojeda, Francisco, Kontto, Jukka, Landmesser, Ulf, Kuulasmaa, Kari, and Blankenberg, Stefan
Abstract: Aims: As promising compounds to lower Lipoprotein(a) (Lp(a)) are emerging, the need for a precise characterization and comparability of the Lp(a)-associated cardiovascular risk is increasing. Therefore, we aimed to evaluate the distribution of Lp(a) concentrations across the European population, to characterize the association with cardiovascular outcomes and to provide high comparability of the Lp(a)-associated cardiovascular risk by use of centrally determined Lp(a) concentrations. Methods and results: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE)-project, we analysed data of 56 804 participants from 7 prospective population-based cohorts across Europe with a maximum follow-up of 24 years. All Lp(a) measurements were performed in the central BiomarCaRE laboratory (Biokit Quantia Lp(a)- Test; Abbott Diagnostics). The three endpoints considered were incident major coronary events (MCE), incident cardiovascular disease (CVD) events, and total mortality. We found lower Lp(a) levels in Northern European cohorts (median 4.9mg/dL) compared to central (median 7.9mg/ dL) and Southern European cohorts (10.9 mg/dL) (Jonckheere-Terpstra test P< 0.001). Kaplan-Meier curves showed the highest event rate of MCE and CVD events for Lp(a) levels≥90th percentile (log-rank test: P< 0.001 for MCE and CVD). Cox regression models adjusted for age, sex, and cardiovascular risk factors revealed a significant association of Lp(a) levels with MCE and CVD with a hazard ratio (HR) of 1.30 for MCE [95% confidence interval (CI) 1.15- 1.46] and of 1.25 for CVD (95% CI 1.12-1.39) for Lp(a) levels in the 67-89th percentile and a HR of 1.49 for MCE (95% CI 1.29-1.73) and of 1.44 for CVD (95% CI 1.25-1.65) for Lp(a) levels≥ 90th percentile vs. Lp(a) levels in the lowest third (P< 0.001 for all). There was no significant association between Lp(a) levels and total mortality Subgroup analysis for a continuous version of cube root transformed Lp(a)
Published: 2017

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

23 results on '"Brunner, Fabian J"'

1. C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease:the BiomarCaRE project

2. Deep learning for calcium segmentation in intravascular ultrasound images

3. Deep learning for guidewire detection in intravascular ultrasound images

4. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

5. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

6. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

7. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

8. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

9. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

10. Application of non-HDL cholesterol for population-based cardiovascular risk stratification:results from the Multinational Cardiovascular Risk Consortium

11. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium

12. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

13. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

14. Application of non-HDL cholesterol for population-based cardiovascular risk stratification:results from the Multinational Cardiovascular Risk Consortium

15. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium

16. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

17. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

18. Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium

19. Application of non-HDL cholesterol for population-based cardiovascular risk stratification:results from the Multinational Cardiovascular Risk Consortium

20. Gender-specific diagnostic performance of a new high-sensitivity cardiac troponin I assay for detection of acute myocardial infarction

21. Gender-specific diagnostic performance of a new high-sensitivity cardiac troponin I assay for detection of acute myocardial infarction

22. Lipoprotein(a) and the risk of cardiovascular disease in the European population:Results from the BiomarCaRE consortium

23. Lipoprotein(a) and the risk of cardiovascular disease in the European population:Results from the BiomarCaRE consortium

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Publication Year Range

Publication Type

Database

Publisher

23 results on '"Brunner, Fabian J"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources